Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifestyle interventions after addition of Januvia to metformin in type 2 diabetes mellitus
2007-000755-33Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: HbA1c target achievement at 24 weeks and HbA1c level. Started Mar 2007; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-000755-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000755-33.